Takeda Pharmaceutical reports a 1.7% year-over-year revenue decline but maintains strong cash flow and forecasts FY2026 targets.
Takeda Pharmaceutical reported a non-GAAP EPS of ¥517.00 and revenue of ¥4505.7 billion for the fiscal year, marking a 1.7% decline year-over-year. The company attributed the revenue drop to market conditions but highlighted stability in other financial metrics.
Adjusted free cash flow reached JPY 684.5 billion, aligning with earlier forecasts. The company ended the fiscal year with a robust cash balance, reinforcing financial resilience amid revenue pressures.
Takeda also provided its full-year forecast for FY2026, signaling long-term strategic planning despite near-term challenges.